STAT Wunderkinds: 5 years of progress
STAT is joined by a group of the first Wunderkinds class to discuss their experiences and lessons learned since joining their cohort in 2017.
Health plans need to address health inequities as part of their core work
Health plans, in collaboration with their members, the medical community, and others, can make meaningful reductions in health inequities.
Watch: Experts challenge Lilly exec on effectiveness of Alzheimer’s drug
Lilly’s data on an experimental Alzheimer’s drug and its ability to clear amyloid plaques came under question by experts at the STAT Summit.
Biotech companies scramble to find scientists to manage troves of data
Research institutions and biotech companies are generating more data than ever, but there just aren’t enough data scientists.
FDA approves first drug for genetic cause of dwarfism
The FDA approved the first treatment for the most common cause of dwarfism Friday, a drug that has proved to increase children’s height.
FDA expands emergency use for Pfizer, Moderna Covid boosters
A proposal for the WTO to temporarily waive intellectual property rights and widen access to Covid-19 products appears unlikely to pass.
SARS-CoV-2 genomics as a springboard for future disease mitigation in LMICs
This Genome Watch highlights how the SARS-CoV-2 pandemic laid the groundwork for continued use of real-time genomic epidemiology for public health responses in low-and-middle-income countries.
NASA spacecraft will slam into asteroid to test Earth-protection plan
DART mission is first to try out a strategy for shielding the planet from killer asteroids.
A new, gel-based wearable can catch infections before the naked eye can
In preliminary testing, the wearable identified infections in open wounds before they looked any different than uninfected wounds.
Scientists question Max Planck Society’s treatment of women leaders
An open letter signed by 145 female scientists from across the world expresses concern over recent dismissals of women leaders